Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806778 | 0.95 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL27782829 | 0.89 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL9816200 | 0.89 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL22305405 | 0.84 | SLC6A4 (0.81) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL5139722 | 0.82 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL14035499 | 0.82 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL11801805 | 0.82 | SLC6A4 (0.83) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL12806785 | 0.81 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL10413788 | 0.80 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL12806743 | 0.79 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062015-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252789-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, SPHK2, S1PR3 | SLC6A4 2155/4885SLC6A2 1371/4885SLC6A3 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.